Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on precision medicines for oncology, with its initial emphasis on hematologic cancers. Its lead asset, tuspetinib, is being developed for acute myeloid leukemia (AML), including combination regimens intended to improve outcomes in newly diagnosed and relapsed/refractory patients. The company also has a broader small-molecule pipeline aimed at enhancing anti-cancer therapy without overlapping toxicities. Aptose is headquartered in Toronto, Canada, with executive offices in San Diego, California, and currently has no marketed products.
0.69
0.69
| % | |
|---|---|
| Lead clinical oncology programs | 80% Tuspetinib and related AML development activities, including monotherapy and combination regimens. |
| Clinical trial collaboration services | 10% Research collaboration and trial participation with NCI/CTEP and other clinical networks. |
| Pipeline discovery and development | 10% Earlier-stage small-molecule oncology assets such as luxeptinib and related platform work. |
Aptose does not sell commercial products to traditional end customers; its primary counterparties are research...
NCI, CTEP, NCTN, NCORP and other research partners that help run trials and generate clinical evidence for tuspetinib.
Hospitals and cancer centers that enroll patients in studies and would adopt approved AML therapies.
Specialists who would use Aptose therapies if approved, especially in AML and MDS settings.
Patients with molecularly defined or relapsed/refractory disease who need more effective treatment options.
Aptose is operationally split between the United States and Canada, with executive offices in San Diego and a head...
Aptose’s strategy is centered on advancing tuspetinib through precision-medicine AML development paths that can support...
Tuspetinib is the company’s lead value driver and the main path to future approval or partnering.
Combination regimens may improve response rates and create a stronger commercial and regulatory profile than monotherapy alone.
The company has going-concern risk and needs capital to continue trials and manufacturing.
Aptose faces substantial going-concern and financing risk because it has no material product revenue and limited cash...
Management disclosed that cash is insufficient to fund operations for the next 12 months without substantial financing or restructuring.
The company relies on equity, debt, collaborations, or other financing to fund trials and overhead.
Tuspetinib is still in clinical development and may not meet efficacy/safety thresholds for approval.
The company depends on third parties for manufacturing and trial execution, and one CRO represented a large share of accounts payable.
Imported goods and global supply chains may be affected by tariffs, regulation, and geopolitical tensions.
APVO · Pharmaceutical Preparations
APUS · Pharmaceutical Preparations
ATOS · Pharmaceutical Preparations
ADPT · Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp is a Seattle-based life sciences company built around immune-system sequencing and computational biology.
APGE · Biological Products, (No Diagnostic Substances)
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
: 11/08/2026